Advertisement

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

  • Dan Călugăru
  • Mihai Călugăru
Letter to the Editor

Dear Editor:

We would like to address several challenges that have arisen from the study by Morimoto et al. [1], which are specifically summarized below.

Several relevant data are missing from the study (Table 1).
Table 1

Missing data from the article by Morimoto et al. (1)

Variables

 

 PCV duration before entry into the study

 The anatomic types of macular edema (diffuse/subretinal fluid/cystic changes within neurosensory retina/mixed type) at presentation and at year 2

 The proportions of the eyes with complete regression of polypoidal lesions and complete dry macula at year 2

 The proportion of the eyes with recurrent exudative changes up to the end of the study

 The anatomic lesions of the PCV (serosanguineous detachments of RPE and neurosensory retina, polypoidal lesions, abnormal branch vascular networks, vitrous hemorrhage, subretinal fibrosis, pigment epithelial hyperplasia, and atrophic degeneration) at baseline and at the end of the follow-up

 The quantification of the...

Keywords

Aflibercept Treat-and-extend regimen Polypoidal choroidal vasculopathy Central macular thickness Central choroidal thickness 

Notes

Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

References

  1. 1.
    Morimoto M, Matsumoto H, Mimura K, Akiyama H (2017) Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol,  https://doi.org/10.1007/s00417-017-3718-6 Published online: July 01, 2017
  2. 2.
    Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K (2013) Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol 91(6):e474–e481CrossRefPubMedGoogle Scholar
  3. 3.
    Jeong S, Sagong M (2017) Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy. Br J Ophthalmol 101(6):758–763CrossRefPubMedGoogle Scholar
  4. 4.
    Călugăru D, Călugăru M (2017) Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 174(2):181–182PubMedGoogle Scholar
  5. 5.
    Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31(6):357–362CrossRefPubMedGoogle Scholar
  6. 6.
    Julien S, Biesemeier A, Taubitz T, Schraemeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues on monkey eyes. Br J Ophthalmol 98(6):813–825CrossRefPubMedGoogle Scholar
  7. 7.
    Jaffe GJ, Kaiser PK, Thompson D, Gibson A, Saroj N, Vitti R, Berliner AJ, Heier JS (2016) Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology 123(9):1856–1864CrossRefPubMedGoogle Scholar
  8. 8.
    Hikichi T (2017) Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy. Br J Ophthalmol.  https://doi.org/10.1136/bjophthalmol-2017-310448 Published on May 25, 2017
  9. 9.
    Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovacular age-related macular degeneration. Am J Ophthalmol 173(1):145–146PubMedGoogle Scholar
  10. 10.
    Călugăru D, Călugăru M (2017) Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol 174(2):185–186PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-NapocaCluj-NapocaRomania

Personalised recommendations